{"title":"The role of 68Ga-Pentixafor PET in Primary Aldosteronism: a systematic review and meta-analysis","authors":"Min Wang, Jiayu Zhang, Bin Wu, Chunyin Zhang","doi":"10.1007/s40336-023-00610-3","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>The objective of this research is to conduct a thorough evaluation, both quantitatively and qualitatively, of the effectiveness of <sup>68</sup>Ga-Pentixafor PET within the Primary Aldosteronism framework.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We systematically searched the PubMed and Embase databases for relevant studies concerning the use of <sup>68</sup>Ga-Pentixafor PET in Primary Aldosteronism, spanning from the inception of these databases up to September 1, 2023. We assessed the quality of the chosen literature employing the QUADAS-2 diagnostic test evaluation tool. Following this, we conducted comprehensive analyses, both quantitatively and qualitatively, on relevant outcome measures extracted from the selected literature.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>This study incorporated 7 articles encompassing a total of 474 patients. Among these articles, seven studies assessed the accuracy of <sup>68</sup>Ga-Pentixafor PET in distinguishing between different subtypes of Primary Aldosteronism, namely aldosterone-producing adenoma and non-aldosterone-producing adenoma. Of these, four studies presented complete 2 × 2 contingency tables for visual analysis, and three studies provided complete 2 × 2 contingency tables for semi-quantitative analysis. In addition, six studies reported the correlation between <sup>68</sup>Ga-Pentixafor PET findings and the clinical characteristics of patients. Furthermore, five studies explored the relationship between <sup>68</sup>Ga-Pentixafor PET outcomes and the clinical prognosis of patients. Five studies also investigated the correlation between <sup>68</sup>Ga-Pentixafor PET results and immunohistochemistry, whereas four studies assessed the link between <sup>68</sup>Ga-Pentixafor PET and nodule size.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p><sup>68</sup>Ga-Pentixafor PET displays substantial promise in enhancing the diagnosis of Primary Aldosteronism subtypes and precisely localizing aldosterone-producing adenoma. Furthermore, <sup>68</sup>Ga-Pentixafor PET imaging exhibits significant correlations with the clinical characteristics, clinical prognosis, immunohistochemistry, and nodule size in Primary Aldosteronism patients.</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"26 1","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40336-023-00610-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
The objective of this research is to conduct a thorough evaluation, both quantitatively and qualitatively, of the effectiveness of 68Ga-Pentixafor PET within the Primary Aldosteronism framework.
Methods
We systematically searched the PubMed and Embase databases for relevant studies concerning the use of 68Ga-Pentixafor PET in Primary Aldosteronism, spanning from the inception of these databases up to September 1, 2023. We assessed the quality of the chosen literature employing the QUADAS-2 diagnostic test evaluation tool. Following this, we conducted comprehensive analyses, both quantitatively and qualitatively, on relevant outcome measures extracted from the selected literature.
Results
This study incorporated 7 articles encompassing a total of 474 patients. Among these articles, seven studies assessed the accuracy of 68Ga-Pentixafor PET in distinguishing between different subtypes of Primary Aldosteronism, namely aldosterone-producing adenoma and non-aldosterone-producing adenoma. Of these, four studies presented complete 2 × 2 contingency tables for visual analysis, and three studies provided complete 2 × 2 contingency tables for semi-quantitative analysis. In addition, six studies reported the correlation between 68Ga-Pentixafor PET findings and the clinical characteristics of patients. Furthermore, five studies explored the relationship between 68Ga-Pentixafor PET outcomes and the clinical prognosis of patients. Five studies also investigated the correlation between 68Ga-Pentixafor PET results and immunohistochemistry, whereas four studies assessed the link between 68Ga-Pentixafor PET and nodule size.
Conclusion
68Ga-Pentixafor PET displays substantial promise in enhancing the diagnosis of Primary Aldosteronism subtypes and precisely localizing aldosterone-producing adenoma. Furthermore, 68Ga-Pentixafor PET imaging exhibits significant correlations with the clinical characteristics, clinical prognosis, immunohistochemistry, and nodule size in Primary Aldosteronism patients.
期刊介绍：
Clinical and Translational Imaging is an international journal that publishes timely, up-to-date summaries on clinical practice and translational research and clinical applications of approved and experimental radiopharmaceuticals for diagnostic and therapeutic purposes. Coverage includes such topics as advanced preclinical evidence in the fields of physics, dosimetry, radiation biology and radiopharmacy with relevance to applications in human subjects. The journal benefits a readership of nuclear medicine practitioners and allied professionals involved in molecular imaging and therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
